News

According to the company, EYP-1901 is an investigational sustained delivery therapy containing vorolanib, a selective tyrosine kinase inhibitor formulated in bioerodible Durasert E.

Student confidence in dealing with ophthalmic conditions is down, deterring them from considering ophthalmology as a career.

The data indicated that patients with Alzheimer’s disease who were treated with acetylcholinesterase inhibitors had a slightly lower hazard of developing AMD compared with untreated patients.

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME.

The company’s ANX007 global pivotal program in geographic atrophy is expected to start in mid-2024. It is the first pivotal trial to use vision preservation as a primary outcome measure in GA.

Sharing, learning, networking, collaborating

A reduction in clinical exposure has harmed student confidence, according to a questionnaire administered in the United Kingdom

eSight’s medical equipment enhances vision for individuals with over 20 distinct ocular disorders, frequently enabling users to attain 20/20 vision. The Consumer Electronics Show runs January 9-12 in Las Vegas.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

The European Union approval applies to aflibercept 8 mg for treatment of nAMD and DME

According to OKYO Pharma, the first-in-human, randomized, double-masked, placebo-controlled trial of OK-101 “established a clear and informed path for further development in Phase 3 registration trials.”

The device is intended for use for LASIK vision correction surgery for myopia and myopic astigmatism.

Researchers found the administration of the neuropeptide α–melanocyte–stimulating hormone promotes corneal healing and restores normal eye function to an otherwise degenerating and diseased cornea by providing protection against cell death and promoting cell regeneration.

In a letter to shareholders, Ricciardi provided updates on Cognition’s 2024 pipeline and expected advances for several diseases.

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

The Retina Program 2024 will convene during the Hawaiian Eye meeting in Maui from January 14 through January 19

The company announced more advancements of its RASP modulator platform, including plans for ADX-629 and ADX-246.

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

This partnership will provide Greater Tampa Bay community with services for the treatment of uveitis and retina care.

Albert S Jun, MD, PhD, comes to UVA from the Johns Hopkins University School of Medicine.

If granted, this device would be assigned an official classification as a Class II device with special controls.

Hawaiian Eye and Retina 2024 meetings will take place from January 13 to 19 at the Grand Wailea Maui, 3850 Wailea Alanui Drive, Wailea, HI.

Data will be shared in early 2024 regarding this potential treatment of diabetic retinopathy via eye drop.

The study will evaluate the safety and efficacy of fluocinolone acetonide intravitreal implant 0.18mg, (YUTIQ) in the treatment of chronic non-infectious uveitis and related intraocular inflammation.

Prevent Blindness will offer downloadable fact sheets, shareable social media graphics and educational videos for patients

The revision is in response to multiple recalls for eye drops and instances of consumer injury and death in 2023.

The study illustrates efficacy of AVT06 as compared with aflibercept (Eylea) for neovascular age-related macular degeneration

According to the company, Phase 3 startup activities are underway, and the clinical trial is expected to start in the first quarter of 2024.